PMA device
VITROS Immunodiagnostic Products Anti-HBc Reagent Pack and Calibrator
Ortho-Clinical Diagnostics · Test, Hepatitis B (B Antigen, B Surface Antigen, Be Antigen) (LOM, Class II) · First FDA decision Apr 19, 2001, newest Dec 17, 2018HIV, hepatitis and sexually transmitted infections
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
27
PMA pathway
Device trials
0
Naming "VITROS Immunodiagnostic Products"
MAUDE reports
2,398
Brand "VITROS Immunodiagnostic Products", since 2015
PubMed studies
13
Mentioning "VITROS Immunodiagnostic Products"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing VITROS Immunodiagnostic Products Anti-HBc Reagent Pack and Calibrator
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology, with pictures of the device
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 6 of 27 decisions filed under this name.
P030024-S028 · Decided Dec 17, 2018 · 62 days after receipt · Normal 180 Day Track No User Fee
Device type: Test, Hepatitis B (B Antigen, B Surface Antigen, Be Antigen) (LOM) · Laboratory Medicine & Pathology
5 more FDA decisions with a free account
Older decisions: P090028-S013, P090028-S010, P090028, P030026-S035, P030026-S034, P030026-S032, P030026-S016, P030024-S026, P030024-S025, P030024-S010, P000044-S039, P000044-S038, P000044-S037, P000044-S019, P000044, P000014-S034, P000014-S033, P000014-S032, P000014-S020, P000014-S017, P000014-S004
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Hepatitis Panel/Acute Hepatitis PanelNational determinationOn the books190.33Updated Oct 1, 2026
- Screening for Hepatitis C Virus (HCV) in AdultsNational analysisUnder reviewCAG-00436RUpdated Sep 23, 2026
- Screening for Hepatitis C Virus (HCV) in AdultsNational analysisReview closedCAG-00436NUpdated Sep 22, 2026
- Screening for Hepatitis B Virus (HBV) InfectionNational analysisReview closedCAG-00447NUpdated Sep 22, 2026
- Hepatitis Panel/Acute Hepatitis Panel (Addition of ICD-9-CM 790.5, Other nonspecific abnormal serum enzyme levels, as a covered indication)Coding analysisReview closedCAG-00335NUpdated Sep 14, 2026
- Hepatitis Panel/Acute Hepatitis Panel (Addition of ICD-9-CM 790.4, Elevation of Levels of Transaminase or Lactic Acid Dehydrogenase)Coding analysisReview closedCAG-00304NUpdated Sep 14, 2026
- Hepatitis Panel (Removal of ICD-9-CM Code 784.69, Other symbolic dysfunction, from the list of Codes Covered by Medicare)Coding analysisReview closedCAG-00283NUpdated Sep 14, 2026
- Screening for Hepatitis C Virus (HCV) in AdultsNational determinationOn the books210.13Updated Apr 7, 2026
Clinical trials
Device studies on ClinicalTrials.gov that name "VITROS Immunodiagnostic Products", any status and sponsor, newest update first.
No registered device study names "VITROS Immunodiagnostic Products".
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "VITROS Immunodiagnostic Products", and for the whole product code for context.
This brand
2,398 reports: 2,388 malfunction, 10 injury, 0 death
Whole product code LOM
2,194 reports: 2,179 malfunction, 14 injury, 0 death
Newest reports for this brand
Ortho-Clinical Diagnostics, Inc.
3007111389-2026-00163 · Received Oct 16, 2026 · Event dated Sep 17, 2026
Device type: General Purpose Reagent (PPM)
Device problem as coded: Low Test Results
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
4 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
Z-0687-2019 · Started Nov 1, 2018
Reason given: The firm is extending their previous July 2018 recall to include additional product codes. Biased results may occur for these additional products at biotin concentrations which are lower than indicated in the current Instructions for Use.
Cause as FDA categorized it: Device Design · Device type: Test, Hepatitis B (B Antigen, B Surface Antigen, Be Antigen) (LOM)
1 more recall records with a free account
Published research
The most relevant PubMed records for "VITROS Immunodiagnostic Products"[tiab]. The summary above synthesizes these.
- Analytical performance of the VITROS® Immunodiagnostic Products total PSA II and free PSA assays.
De Keukeleire S, Wauters A, Luyts D, et al. · Clin Biochem · 2014Comparative Study, Research Support, Non-U.S. Gov't
- Clinical Performance of an N-Terminal Pro-B-Type Natriuretic Peptide Assay in Acute Heart Failure Diagnosis.
Daniels LB, Ajongwen P, Christenson RH, et al. · J Appl Lab Med · 2025Multicenter Study
- Examination of SARS-CoV-2 serological test results from multiple commercial and laboratory platforms with an in-house serum panel.
Lester SN, Stumpf M, Freeman BD, et al. · Access Microbiol · 2024
- Technical and clinical evaluation of the VITROS® Immunodiagnostic Products 25-OH Vitamin D Total Assay--comparison with marketed automated immunoassays and a liquid chromatography-tandem mass spectrometry method.
Cavalier E, Rousselle O, Ferrante N, et al. · Clin Chem Lab Med · 2013Comparative Study, Research Support, Non-U.S. Gov't
- Clinical evaluation of four commercial immunoassays for the detection of antibodies against established SARS-CoV-2 infection.
Chua KYL, Vogrin S, Bittar I, et al. · Pathology · 2020Comparative Study
- Bimodal distributions of anti-Trypanosoma cruzi antibody levels in blood donors are associated with parasite detection and antibody waning in peripheral blood.
Remesar MC, Sabino EC, Buss LF, et al. · PLoS Negl Trop Dis · 2025Research Support, N.I.H., Extramural
- Declining antibody levels to Trypanosoma cruzi correlate with polymerase chain reaction positivity and electrocardiographic changes in a retrospective cohort of untreated Brazilian blood donors.
Buss LF, Campos de Oliveira-da Silva L, Moreira CHV, et al. · PLoS Negl Trop Dis · 2020Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
- Is Sunshine Vitamin Related to Adolescent Depression? A Cross-Sectional Study of Vitamin D Status and Depression Among Rural Adolescents.
Tarikere Satyanarayana P, Suryanarayana R, Theophilus Yesupatham S, et al. · Cureus · 2023
- Clinical and Analytical Performance Evaluation of an Automated Procalcitonin Assay.
Ogbonna G, Atienza JR, Singleton DW, et al. · J Appl Lab Med · 2025Evaluation Study
- Impaired Antibody Response to the BNT162b2 Messenger RNA Coronavirus Disease 2019 Vaccine in Patients With Systemic Lupus Erythematosus and Rheumatoid Arthritis.
Ammitzbøll C, Bartels LE, Bøgh Andersen J, et al. · ACR Open Rheumatol · 2021
- Clinical Use of a New High-Sensitivity Cardiac Troponin I Assay in Patients with Suspected Myocardial Infarction.
Boeddinghaus J, Twerenbold R, Nestelberger T, et al. · Clin Chem · 2019Multicenter Study, Observational Study
- 0/2ߙh-Algorithm for Rapid Triage of Suspected Myocardial Infarction Using a Novel High-Sensitivity Cardiac Troponin I Assay.
Wildi K, Boeddinghaus J, Nestelberger T, et al. · Clin Chem · 2022
Other devices of this type
Also filed under product code LOM.
- Elecsys Anti-HBc IgM and PreciControl Anti-HBc IgMRoche Diagnostics Corp. · PMA 2024
- Advia Centaur Hbc IGM Readypack ReagentsSiemens Healthcare Diagnostics · PMA 2016
- Immulite/Immulite 1000 & Immulite 2000 Anti-HbsSiemens Healthcare Diagnostics Products, Ltd. · PMA 2010
- Architect AusabAbbott Laboratories, Inc. · PMA 2024
- Elecsys HBsAg IIRoche Diagnostics, Inc. · PMA 2023
- Elecsys Anti-HBc IIRoche Diagnostics Corp. · PMA 2023
- Architect Core-MAbbott Laboratories · PMA 2020
- ADVIA Centaur HBsAgII (HBsII)Siemens Corp. · PMA 2025
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.